---
title: "SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291062209.md"
description: "The Schall Law Firm is investigating ARS Pharmaceuticals (NASDAQ: SPRY) for potential securities law violations, including false statements or failure to disclose material information. This follows a sharp drop in ARS shares on June 24, 2026, after its flagship product Neffy failed to secure new formulary additions, contradicting prior executive optimism. Investors who suffered losses are encouraged to contact the firm to discuss their rights."
datetime: "2026-06-28T16:09:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291062209.md)
  - [en](https://longbridge.com/en/news/291062209.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291062209.md)
generator: "portal-rs"
---

# SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

**SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm**

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (NASDAQ: SPRY) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. ARS shares dropped sharply in after-hours trading on June 24, 2026, based on the news that its flagship product Neffy failed to secure new formulary additions in the current review cycle. This news followed optimistic statements by the Company’s CEO and other executives, who anticipated "being on formulary for CVS Caremark, Anthem, Aetna and others by July 1 in time for the summer peak prescribing season."

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

The Schall Law Firm  
Brian Schall, Esq.  
310-301-3335  
info@schallfirm.com  
www.schallfirm.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260628169359/en/

### Related Stocks

- [SPRY.US](https://longbridge.com/en/quote/SPRY.US.md)

## Related News & Research

- [20:01 ETSPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit](https://longbridge.com/en/news/296036090.md)
- [Hennion & Walsh Asset Management Inc. Acquires Shares of 175,614 ARS Pharmaceuticals, Inc. $SPRY](https://longbridge.com/en/news/295770946.md)
- [SPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026](https://longbridge.com/en/news/295826002.md)
- [TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law](https://longbridge.com/en/news/296031849.md)
- [JBTM Investors Have Opportunity to Join JBT Marel Corporation Fraud Investigation with SBS Law](https://longbridge.com/en/news/296136950.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**